Cite
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer.
MLA
Garber, Judy E., et al. “Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer.” JNCI: Journal of the National Cancer Institute, vol. 102, no. 13, July 2010, pp. 942–49. EBSCOhost, https://doi.org/10.1093/jnci/djq211.
APA
Garber, J. E., Halabi, S., Tolaney, S. M., Kaplan, E., Archer, L., Atkins, J. N., Edge, S., Shapiro, C. L., Dressler, L., Paskett, E. M., Kimmick, G., Orcutt, J., Scalzo, A., Winer, E., Levine, E., Shahab, N., & Berliner, N. (2010). Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. JNCI: Journal of the National Cancer Institute, 102(13), 942–949. https://doi.org/10.1093/jnci/djq211
Chicago
Garber, Judy E., Susan Halabi, Sara M. Tolaney, Ellen Kaplan, Laura Archer, James N. Atkins, Stephen Edge, et al. 2010. “Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer.” JNCI: Journal of the National Cancer Institute 102 (13): 942–49. doi:10.1093/jnci/djq211.